Solaraze will now be marketed by Bioglan in North America and Europe. Bioglan already has a significant marketing presence in all these major markets and Solaraze will provide us with the opportunity to expand further our marketing activities. Solaraze is a topical gel for actinic keratosis, a pre- cancerous skin condition caused by over exposure to the sun. Solaraze utilises SkyePharma's Hyaluronan Induced Targeting transdermal delivery technology. Age, sun exposure and fair skin are risk factors for the development of actinic keratosis.
Current treatment is by surgical means, which can produce scarring.
However, most patients with actinic keratosis at present do not seek treatment. Increasing awareness of skin cancer is expected to lead to significant growth in the number of patients seeking treatment. SkyePharma PLC SkyePharma PLC, one of the world's leading drug delivery companies, develops and manufactures advanced drug delivery solutions. Its technologies include oral controlled release, injectable, inhalation, topical and nano-particulate systems. Bioglan Pharma Plc Bioglan is a well-established, fully integrated, profitable pharmaceutical company with a proven track record.